2024
Efficient and selective kidney targeting by chemically modified carbohydrate conjugates
Kumar V, Wahane A, Tham M, Somlo S, Gupta A, Bahal R. Efficient and selective kidney targeting by chemically modified carbohydrate conjugates. Molecular Therapy 2024, 32: 4383-4400. PMID: 39532098, PMCID: PMC11638880, DOI: 10.1016/j.ymthe.2024.10.020.Peer-Reviewed Original ResearchProximal convoluted tubulesPeptide nucleic acidConvoluted tubulesNucleic acid analogsDecreased collagen depositionAntisense peptide nucleic acidFibrosis mouse modelCarbohydrate conjugatesKidney disease modelsSystemic deliveryFibrosis progressionSmall moleculesKidney cell lineAdverse reactionsMiR-33Mouse modelBiodistribution studiesImmunofluorescence stainingCollagen depositionKidney targetingTargeted deliveryLigandCell linesEndocytic uptakeAcid analogsAll roads lead to IgA: Mapping the many pathways of IgA induction in the gut
Siniscalco E, Williams A, Eisenbarth S. All roads lead to IgA: Mapping the many pathways of IgA induction in the gut. Immunological Reviews 2024, 326: 66-82. PMID: 39046160, DOI: 10.1111/imr.13369.Peer-Reviewed Original ResearchIgA inductionFood allergyFood-specific IgE.Food-specific IgEAntibody isotypesPrevalence of food allergyT cell helpIncreasing prevalence of food allergyRelease of histamineFoodFood antigensB cellsInduce toleranceAdverse reactionsCommensal bacteriaMast cellsIncreased prevalenceGut immunityIgAGutAllergyAntibodiesIsotypeInductionThe association of FKBP5 gene polymorphism with genetic susceptibility to depression and response to antidepressant treatment- a systematic review
Zhang Y, Yue W, Li J. The association of FKBP5 gene polymorphism with genetic susceptibility to depression and response to antidepressant treatment- a systematic review. BMC Psychiatry 2024, 24: 274. PMID: 38609904, PMCID: PMC11010372, DOI: 10.1186/s12888-024-05717-z.Peer-Reviewed Original ResearchConceptsFKBP5 gene polymorphismsAntidepressant treatmentGene polymorphismsResponse to antidepressant treatmentAntidepressant drug treatmentGenetic susceptibilityAffective disordersAssociated with adverse reactionsDepressionTreatment strategiesAdverse reactionsFKBP5Drug treatmentTreatment sensitivityMethodsElectronic databasesGenetic disordersRs1360780Epigenetic changesReplication studySystematic reviewModerate qualityStudy characteristicsTreatmentData extractionDisorders
2023
Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice
Tran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.Peer-Reviewed Original ResearchConceptsB cell responsesPlatelet transfusionsMajor histocompatibility complexCell responsesPrior exposurePlatelet alloimmunizationMemory B cell responsesPlatelet transfusion recipientsSubsequent platelet transfusionsAllogeneic platelet transfusionsNegative bacterial infectionsPolyinosinic-polycytidylic acidGerminal center formationPrior inflammationAlloantibody responsesAlloimmune responsePlatelet refractorinessFuture transplantTransfusion recipientsMHC tetramersAdverse reactionsInflammatory environmentAntigen experiencePlatelet antigensTransfusionManagement of Severe Allergic-Like Contrast Media Reactions: Pitfalls and Strategies, From the AJR Special Series on Contrast Media.
Asch D, Callahan M, Thomas K, Desai S, Pahade J. Management of Severe Allergic-Like Contrast Media Reactions: Pitfalls and Strategies, From the AJR Special Series on Contrast Media. American Journal Of Roentgenology 2023, 223: e2330044. PMID: 37818959, DOI: 10.2214/ajr.23.30044.Peer-Reviewed Original ResearchDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosisDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsDiHS/DRESSClinicopathological featuresSystemic symptomsDrug reactionsDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromePart I. EpidemiologyVisceral organ involvementCutaneous adverse reactionsRisk of relapseHypersensitivity syndromeOrgan involvementI. EpidemiologyOrgan dysfunctionSignificant morbidityAutoimmune diseasesAdverse reactionsDrug exposureT cellsCommon triggerImmune systemPathogenesisEosinophiliaMedical education activitiesAdverse Events Associated With Bioabsorbable Nasal Implants: A MAUDE Database Analysis
Wilkins S, Sheth A, Kayastha D, Abdou H, Salehi P, Citardi M, Manes R. Adverse Events Associated With Bioabsorbable Nasal Implants: A MAUDE Database Analysis. Otolaryngology 2023, 168: 1253-1257. PMID: 36939542, DOI: 10.1002/ohn.227.Peer-Reviewed Original ResearchConceptsAdverse eventsNasal implantsPotential long-term complicationsMAUDE Database AnalysisLong-term complicationsPain/discomfortUser Facility Device Experience (MAUDE) databaseNasal valve collapseSteroid injectionTreatment sequelaeStandardized reporting templateCommon symptomsAdverse reactionsPathologic analysisValve collapseImplant protrusionAdjacent tissuesMAUDE databaseDevice reportsReporting templateDatabase analysisBioabsorbable implantsComplicationsImplantsExperience databaseCutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study
del Mar Castro M, Rode J, Machado P, Llanos-Cuentas A, Hueb M, Cota G, Rojas I, Orobio Y, Sarmiento O, Rojas E, Quintero J, Pimentel M, Soto J, Suprien C, Alvarez F, Ramos A, dos Santos Arantes R, da Silva R, Arenas C, Vélez I, Lyra M, Saravia N, Arana B, Alexander N. Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study. PLOS Neglected Tropical Diseases 2023, 17: e0011029. PMID: 36689465, PMCID: PMC9894540, DOI: 10.1371/journal.pntd.0011029.Peer-Reviewed Original ResearchConceptsCollaborative retrospective studyRetrospective studyAdverse reactionsCutaneous leishmaniasisAge groupsMedian lesion diameterOverall cure rateOlder adult patientsMost adverse reactionsCutaneous leishmaniasis treatmentYears of ageMonotherapy regimenAdult patientsReferral centerLocal therapyPediatric populationClinical recordsCure rateCL patientsTherapeutic responseClinical trialsDisease presentationMedian numberMild intensityAntileishmanial treatmentNeurological sequelae of vaccines
McAlpine L, Zubair A. Neurological sequelae of vaccines. Neurological Sciences 2023, 44: 1505-1513. PMID: 36622478, PMCID: PMC9838503, DOI: 10.1007/s10072-022-06581-z.Peer-Reviewed Original ResearchConceptsGuillain-Barre syndromeInfectious diseasesNeurological sequelaeAcute disseminated encephalomyelitisSystemic immune activationMild adverse reactionsDisseminated encephalomyelitisLocal sorenessNeurologic sequelaeTransverse myelitisAdverse eventsRecent vaccinationImmune activationAdverse reactionsDisease onsetPotential pathogenesisSafe optionPotential treatmentEarly identificationVaccineSequelaeRapid diagnosisAdverse effectsTypical symptomsDisease
2022
Chemical Structural Alert and Reactive Metabolite Concept as Applied in Medicinal Chemistry to Minimize the Toxicity of Drug Candidates
NASSAR A. Chemical Structural Alert and Reactive Metabolite Concept as Applied in Medicinal Chemistry to Minimize the Toxicity of Drug Candidates. 2022, 345-372. DOI: 10.1002/9781119851042.ch11.Peer-Reviewed Original ResearchAryl hydroxamic acidsDrug candidatesMedicinal chemistryChemical groupsQuinone methideChemical structural alertsReactive metabolitesArylpropionic acidsStructural alertsLarge clinical trialsHydroxamic acidPreclinical safety studiesToxicity problemsToxicity warningExamples of drugsPotential toxicityAdverse reactionsClinical trialsMedium-chain fatty acidsSide effectsStable metaboliteAcidHuman drugsSafety studiesNitroaromaticsSynthetic Post-Contrast Imaging through Artificial Intelligence: Clinical Applications of Virtual and Augmented Contrast Media
Pasquini L, Napolitano A, Pignatelli M, Tagliente E, Parrillo C, Nasta F, Romano A, Bozzao A, Di Napoli A. Synthetic Post-Contrast Imaging through Artificial Intelligence: Clinical Applications of Virtual and Augmented Contrast Media. Pharmaceutics 2022, 14: 2378. PMID: 36365197, PMCID: PMC9695136, DOI: 10.3390/pharmaceutics14112378.Peer-Reviewed Original ResearchApplication of artificial intelligencePost-contrast imagesArtificial intelligenceApplications of virtualizationAI computational modelsContrast mediumBiomedical imagingAI applicationsAI modelsRisk of adverse reactionsNon-contrast imagesInput dataIntelligenceAdverse reactionsContrast MediaImagesClinical practiceComputational modelClinical applicationSafety Considerations for Natural Products Commonly Used By Patients with Allergic Disease
Soffer G, Shroff P, Horwitz R. Safety Considerations for Natural Products Commonly Used By Patients with Allergic Disease. The Journal Of Allergy And Clinical Immunology In Practice 2022, 10: 3131-3138. PMID: 36174919, DOI: 10.1016/j.jaip.2022.09.025.Peer-Reviewed Original ResearchConceptsConventional medical therapyHealth care providersMedical therapyAllergic diseasesClinical commentaryAdverse reactionsDrug Administration requirementsCare providersSide effectsAlternative medicinePatientsDietary supplementsU.S. FoodAllergyAdministration requirementsMedicinal plantsNatural productsTherapyCliniciansSafety considerationsDiseaseEfficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis
Oh S, Purja S, Shin H, Kim M, Park S, Kronbichler A, Smith L, Eisenhut M, Shin J, Kim E. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis. Vaccines 2022, 10: 1572. PMID: 36298440, PMCID: PMC9608197, DOI: 10.3390/vaccines10101572.Peer-Reviewed Original ResearchNetwork Meta-AnalysisSafety of COVID-19 vaccinesMeta-analysisAdverse reactionsCOVID-19 vaccineSystemic adverse reactionsMRNA-1273 vaccineNeutralizing antibody responsesModerate risk of biasPre-Delta eraLive SARS-CoV-2Systematic reviewRandomized Controlled TrialsRisk of biasPlatform vaccinesMRNA-1273Comparative efficacyLow incidenceMedRxiv databasesCoronaVac vaccineAntibody responseVaccine efficacyControlled TrialsModerate riskSARS-CoV-2Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure
Rodriguez J, Tormey C. Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure. Immunohematology 2022, 38: 96-99. PMID: 36190197, DOI: 10.21307/immunohematology-2022-049.Peer-Reviewed Case Reports and Technical NotesConceptsAmerican Rare Donor ProgramRed blood cell unitsAntigen-positive unitsLife-saving procedurePotential clinical significanceMultiple comorbiditiesKnee amputationExtremity amputationCritical anemiaCase reportAdverse reactionsClinical significanceCell unitsPatient plasmaTransfusion communityGroup OClinical necessityDonor ProgramRBC unitsPatientsAmputationCompatible unitsAnemiaChallenging caseRare eventClinical experience with sesame oral immunotherapy and a quality-of-life assessment
You L, Soffer G, Factor J. Clinical experience with sesame oral immunotherapy and a quality-of-life assessment. Journal Of Food Allergy 2022, 4: 1-9. PMID: 39021386, PMCID: PMC11250642, DOI: 10.2500/jfa.2022.4.220003.Peer-Reviewed Original ResearchOral immunotherapyRespiratory reactionsMaintenance therapyGastrointestinal reactionsSesame allergyCutaneous reactionsFood Allergy QualityFurther prospective studiesYears of ageQuality of lifeFood-related anxietyAdverse eventsPatient chartsProspective studyLife QuestionnaireAdverse reactionsAllergic reactionsFemale genderClinical experiencePatientsDietary limitationsTherapyPrivate practiceU.S. populationOddsThe role of alcohol intake in the pharmacogenetics of treatment with clozapine
Monroy-Jaramillo N, Martínez-Magaña JJ, Pérez-Aldana BE, Ortega-Vázquez A, Montalvo-Ortiz J, López-López M. The role of alcohol intake in the pharmacogenetics of treatment with clozapine. Pharmacogenomics 2022, 23: 371-392. PMID: 35311547, DOI: 10.2217/pgs-2022-0006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse reactionsAlcohol intakeConcomitant useSevere adverse reactionsGood therapeutic effectPrecision medicine approachRefractory psychosisAtypical antipsychoticsInterindividual responseTherapeutic effectClozapineMedicine approachPharmacogenetic studiesSignificant riskIntakePatientsGenetic variantsPharmacogeneticsAntipsychoticsPsychosisCYP1A2ReceptorsSafety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.Peer-Reviewed Original ResearchConceptsHigh-dose groupLow-dose groupMedium-dose groupGeometric mean titresAdverse eventsRecombinant protein vaccineCOVID-19 vaccineSecond vaccinationSARS-CoV-2Day 36Antigen doseAdverse reactionsProtein vaccineMedical conditionsVaccine-related serious adverse eventsHigh-risk medical conditionsInteractive response technology systemAntibody geometric mean titresPre-existing medical conditionsCandidate vaccine formulationsCoV2 preS dTMPrevious phase 1Primary immunogenicity objectivePseudovirus neutralization assayUnsolicited adverse eventsImpact of a pilot multimodal intervention to decrease antibiotic use for respiratory infections in a geriatric clinic
Chauhan L, Huang M, Abdo M, Church S, Fixen D, MaWhinney S, Miller M, Erlandson K. Impact of a pilot multimodal intervention to decrease antibiotic use for respiratory infections in a geriatric clinic. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e1. PMID: 36310812, PMCID: PMC9614947, DOI: 10.1017/ash.2021.238.Peer-Reviewed Original ResearchAntibiotic useAntibiotic prescriptionsOutpatient settingAcute respiratory conditionsAntibiotic order setsOverall antibiotic prescribingTotal antibiotic prescriptionsLong-term followOutpatient antibiotic useBroad-spectrum antibioticsQuality improvement initiativesMixed-effects regression modelsLow-cost interventionAntibiotic use dataAntibiotic durationStop datesAntibiotic guidelinesOlder patientsAntibiotic prescribingInappropriate antibioticsRespiratory infectionsAdverse reactionsSeniors ClinicClinical impactGeriatric clinic
2021
Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Lee S, Yang J, Jung S, Kim M, Yon D, Lee S, Kang H, Dragioti E, Tizaoui K, Jacob L, Koyanagi A, Salem J, Kostev K, Lascu A, Shin J, Kim J, Smith L. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports. European Review For Medical And Pharmacological Sciences 2021, 25: 7390-7397. PMID: 34919240, DOI: 10.26355/eurrev_202112_27435.Peer-Reviewed Original ResearchConceptsAdverse reactionsIndividual case safety reportsReal-world settingsWorld Health Organization databaseCase safety reportsWHO global database of individual case safety reportsSafety reportsPharmacovigilance cohort studyNeural network methodAdverse drug reactionsAssociated with remdesivirBayesian neural network methodCohort studyPandemic outbreak of coronavirus disease 2019Clinical benefitWHO global databaseTreatment of COVID-19Remdesivir useDrug reactionsInformation componentNeuropsychological dysfunctionGS-5734Pharmacovigilance signalsCoronavirus disease 2019Outbreak of coronavirus disease 2019
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply